A Comparison between the Effects of Vaginal Suppository Progesterone vs. the Injection of 17-Alpha Hydroxyprogesterone Caproate on the Duration of Latent Phase After Controlled Threatened Preterm Labor

Women with preterm labor put in an arrest phase by tocolytic therapy, are at increased risk of recurrent preterm labor. The aim of this study is to evaluate vaginal progesterone suppositories as compared to intramuscular type in order to prevent preterm labor in women with episodes of threatened preterm labor.
This prospective longitudinal study was conducted on 108 pregnant
women who were presented with symptoms of threatened preterm labor and went on tocolytic therapy in order to prevent uterine activity. Their gestational age (GA) ranged between 24-34 complete weeks and mothers were at risk of preterm delivery. After acute phase control and delivery supression, 400mg of prophylactic vaginal suppository was prescribed each day in the first intervention group and 250 mg of intra-muscular 17-alpha hydroxyprogesterone caproate was injected once a week in the second intervention group. Treatment continued in both groups up to 36 weeks of gestational age or until delivery.
The prevalence of preterm delivery was significantly higher in patients receiving intra-muscular progesterone (55.6% vs. 37%) (P = 0.05). Moreover, the birth weight in the intramuscular progesterone group was significantly lower than the other group (2685.18 g vs. 2999.25 g) (P = 0/02). First and fifth minute Apgar score were also significantly lower in this group than the vaginal progesterone suppository group (P The results of this study suggest that vaginal progesterone suppository decreases the rate of preterm delivery while it also improves the newborn outcome at a higher rate compared to intra-muscular 17-alpha-hydroxyprogesterone caproate.